Pluvicto Now Approved for More Men With Prostate Cancer
A new FDA approval gives some men with advanced prostate cancer another treatment option.
On July 31, 2026, the U.S. Food and Drug Administration (FDA) approved Pluvicto for some men whose prostate cancer has spread but still responds to hormone therapy.
This is an important change. In the past, Pluvicto was used for men whose cancer had stopped responding to hormone treatment. Now, some men may be able to receive it earlier.
At PCRI, our goal is to help patients understand their options so they can make informed choices with their doctors.
What Is Pluvicto?
Pluvicto is a treatment that uses a small amount of radiation to attack prostate cancer cells.
It works by finding a protein called PSMA. Many prostate cancer cells have this protein on their surface. Pluvicto attaches to those cells and delivers radiation to them.
The treatment is given through a vein.
Who May Benefit?
The new approval is for men who:
Have prostate cancer that has spread to other parts of the body.
Have cancer that still responds to hormone treatment.
Have a PSMA PET scan showing that their cancer has the right target for Pluvicto.
For these patients, Pluvicto is used along with hormone treatment.
Not every man with prostate cancer needs Pluvicto. The best treatment depends on the type of cancer, past treatments, and overall health.
What Did the Research Show?
A large study called PSMAddition found that adding Pluvicto to standard treatment helped keep the cancer from getting worse for a longer time.
This is encouraging news.
However, researchers are still studying whether this approach helps men live longer. Pluvicto is not a cure for prostate cancer.
What About Side Effects?
Like all cancer treatments, Pluvicto has risks.
Some men may have dry mouth, feel tired, or feel sick to their stomach. Pluvicto can also lower blood cell counts or affect the kidneys.
These side effects matter. At PCRI, we believe that understanding the risks of treatment is just as important as understanding the benefits.
What Should Patients Do Next?
If you have prostate cancer that has spread, ask your doctor whether the new Pluvicto approval applies to you.
You may want to ask:
Is my cancer still responding to hormone treatment?
Do I need a PSMA PET scan?
Could Pluvicto help me?
What are the risks and benefits compared with my other options?
The goal is not simply to choose the newest treatment. It is to choose the treatment that makes the most sense for your situation.
At PCRI, we are committed to helping men and their families understand prostate cancer and the choices ahead. Visit pcri.org to explore our free educational resources or contact our Helpline for support.
This article is for educational purposes only and is not a substitute for medical advice.